{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:48:48Z","timestamp":1790948928016,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>Interest in using gene therapy to treat osteoarthritis (OA) is growing and a number of clinical trials have been initiated. This commentary identifies three intersecting areas that need to be addressed for the field to move forward expeditiously. The first relates to lowering the cost of manufacturing clinical grade viral vectors, addressing various aspects of their deployment, and overcoming immune barriers to dosing and re-dosing. The second area requires an improved understanding of the pathophysiology of OA, including its stratification by endotype and phenotype. Coupled to the development of reliable biomarkers, this will enable the creation of personalized gene therapies, facilitate patient selection, and aid the identification of additional molecular targets. Moreover, progress in the early diagnosis of OA will enable administration of gene therapeutics at a stage when they are most likely to be successful. Finally, important issues with regard to financing and regulation are discussed. Top line data from two pivotal Phase III clinical trials are expected to be released this year. The findings from these trials will exercise considerable influence on the future development of the field.<\/jats:p>","DOI":"10.3389\/fbioe.2026.1871809","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:41Z","timestamp":1783316261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["What\u2019s next for osteoarthritis gene therapy?"],"prefix":"10.3389","volume":"14","author":[{"given":"Christopher H.","family":"Evans","sequence":"first","affiliation":[{"name":"Musculoskeletal Gene Therapy Laboratory, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Ghivizzani","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Rehabilitation, University of Florida School of Medicine","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annahita","family":"Keravala","sequence":"additional","affiliation":[{"name":"Genascence Corp.","place":["Palo Alto, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Chalberg","sequence":"additional","affiliation":[{"name":"Genascence Corp.","place":["Palo Alto, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Robbins","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota School of Medicine","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41434-022-00326-5","article-title":"Prevalence of AAV2.5 neutralizing antibodies in synovial fluid and serum of patients with osteoarthritis","volume":"30","author":"Abdul","year":"2023","journal-title":"Gene Ther."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1177\/27702294261430417","volume-title":"Riding the gene therapy rollercoaster into 2026","author":"Albert","year":"2026"},{"key":"B3","article-title":"Extracellular vesicles shield adeno associated virus from neutralization by pre-existing antibody in human synovial fluid while enhancing human osteoarthritic chondrocyte transduction","author":"Atasoy-Zeybek","year":"2026"},{"key":"B4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/dna.1992.11.227","article-title":"Gene transfer to synoviocytes: prospects for gene treatment of arthritis","volume":"11","author":"Bandara","year":"1992","journal-title":"DNA Cell Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12250-020-00250-1","article-title":"Freeze-drying formulations increased the adenovirus and poxvirus vaccine storage times and antigen stabilities","volume":"36","author":"Chen","year":"2021","journal-title":"Virol. Sin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"eadu9804","DOI":"10.1126\/scitranslmed.adu9804","article-title":"A phase 1 clinical trial shows safe, sustained, AAV-Mediated expression of IL-1Ra in the human osteoarthritic knee joint","volume":"17","author":"De la Vega","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41565-025-02101-0","article-title":"A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis","volume":"21","author":"Dewani","year":"2026","journal-title":"Nat. Nanotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/BOR.0000000000000918","article-title":"Osteoarthritis gene therapy in 2022","volume":"35","author":"Evans","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70141","DOI":"10.1002\/jor.70141","article-title":"Osteoarthritis gene therapy: a 30-Year journey from concept to clinical trials","volume":"44","author":"Evans","year":"2026","journal-title":"J. Orthop. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1073\/pnas.0502854102","article-title":"Gene transfer to human joints: progress toward a gene therapy of arthritis","volume":"102","author":"Evans","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/ar2411","article-title":"Arthritis gene therapy's first death","volume":"10","author":"Evans","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.ymthe.2025.07.019","article-title":"Osteoarthritis gene therapy: expanding the scope of genetic therapies","volume":"33","author":"Evans","year":"2025","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMoa0801066","article-title":"Investigation of the cause of death in a gene-therapy trial","volume":"361","author":"Frank","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1038\/s41467-025-64212-5","article-title":"Virus-inspired lipopeptide-derived nucleic acid delivery to cartilage for osteoarthritis therapy","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat8800","article-title":"Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis","volume":"10","author":"Geiger","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/sj.gt.3300486","article-title":"Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy","volume":"4","author":"Ghivizzani","year":"1997","journal-title":"Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1006\/mthe.2002.0562","article-title":"In vivo gene delivery to synovium by lentiviral vectors","volume":"5","author":"Gouze","year":"2002","journal-title":"Mol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/s1525-0016(03)00024-8","article-title":"Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation","volume":"7","author":"Gouze","year":"2003","journal-title":"Mol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/14653249.2011.629645","article-title":"Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients","volume":"14","author":"Ha","year":"2012","journal-title":"Cytotherapy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S589","DOI":"10.1016\/j.joca.2024.02.870","article-title":"Interim data from the first-in-humanphase 1\/2a trial of ICM-203, an intra-articular, AAV gene therapy for osteoarthritis - safety, tolerability, and preliminary evaluation of clinical activity in low dose cohort","volume":"32","author":"Heald","year":"2024","journal-title":"Osteoarthr. Cartil."},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41584-025-01328-4","article-title":"Cam morphology and the development of femoroacetabular impingement syndrome and hip osteoarthritis","volume":"22","author":"Heerey","year":"2026","journal-title":"Nat. Rev. Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.mehy.2012.07.035","article-title":"Intra-articular lentivirus-mediated insertion of the fat-1 gene ameliorates osteoarthritis","volume":"79","author":"Huang","year":"2012","journal-title":"Med. Hypotheses"},{"key":"B23","first-page":"S1288","article-title":"Interim data from the first-in-human phase 1 trial of FX201, an intra-articular, helper-dependent adenoviral gene therapy for osteoarthritis - safety, tolerability, biodistribution, and preliminary evaluation of clinical activity in 5 patients","volume":"29","author":"Kelley","year":"2021","journal-title":"Mol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/jgm.928","article-title":"PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints","volume":"8","author":"Keravala","year":"2006","journal-title":"J. Gene Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/humc.2017.249","article-title":"Double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients","volume":"29","author":"Kim","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-0038-1676803","article-title":"Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-beta1","volume":"33","author":"Lee","year":"2020","journal-title":"J. Knee Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1016\/j.ymthe.2025.05.029","article-title":"Biosafety and efficacy of Kv7 activating rdHSV-CA8 * analgesic gene therapy for chronic pain via the intra-articular route in mice","volume":"33","author":"Levitt","year":"2025","journal-title":"Mol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/mt.2011.303","article-title":"Microvesicle-associated AAV vector as a novel gene delivery system","volume":"20","author":"Maguire","year":"2012","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/biomedicines14010025","article-title":"Lyophilization of adeno-associated virus serotypes for storage and global distribution","volume":"14","author":"McGlinch","year":"2025","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.jot.2025.10.004","article-title":"Targeting synovial inflammation in knee osteoarthritis: translational insights for diagnosis and therapy","volume":"56","author":"Mobasheri","year":"2026","journal-title":"J. Orthop. Transl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.gt.3301014","article-title":"Intra-articular delivery of a Herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis","volume":"6","author":"Oligino","year":"1999","journal-title":"Gene Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.joca.2025.02.785","article-title":"Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment","volume":"33","author":"Pathrikar","year":"2025","journal-title":"Osteoarthr. Cartil."},{"key":"B35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/nejmsb2517623","article-title":"One pivotal trial, the new default option for FDA approval - ending the two-trial dogma","volume":"394","author":"Prasad","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/hum.2018.106","article-title":"Combinatorial Prg4 and Il-1ra gene therapy protects against hyperalgesia and cartilage degeneration in post-traumatic osteoarthritis","volume":"30","author":"Stone","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.actbio.2018.12.004","article-title":"Cartilage penetrating cationic peptide carriers for applications in drug delivery to avascular negatively charged tissues","volume":"93","author":"Vedadghavami","year":"2019","journal-title":"Acta Biomater."},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.joca.2021.09.013","article-title":"Administration of an adeno-associated viral vector expressing interferon-beta in patients with inflammatory hand arthritis, results of a phase I\/II study","volume":"30","author":"Vrouwe","year":"2022","journal-title":"Osteoarthr. Cartil."},{"key":"B39","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/00029330-200608020-00009","article-title":"Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer","volume":"119","author":"Wang","year":"2006","journal-title":"Chin. Med. J. Engl."},{"key":"B40","doi-asserted-by":"publisher","first-page":"120912","DOI":"10.1016\/j.ijpharm.2021.120912","article-title":"Development of a stable lyophilized adeno-associated virus gene therapy formulation","volume":"606","author":"Zhang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2301443","DOI":"10.1002\/smtd.202301443","article-title":"Charge-reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment","volume":"8","author":"Zhang","year":"2024","journal-title":"Small Methods"},{"key":"B42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41434-025-00515-y","article-title":"Co-delivery of IL-1Ra and SOX9 via AAV inhibits inflammation and promotes cartilage repair in surgically induced osteoarthritis animal models","volume":"32","author":"Zhou","year":"2025","journal-title":"Gene Ther."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1871809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:43Z","timestamp":1783316263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1871809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":42,"alternative-id":["10.3389\/fbioe.2026.1871809"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1871809","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1871809"}}